Rubella in the United States: Toward a strategy for disease control and elimination

Epidemiology and Infection

Volumn 107, Issue 1, 1991, Pages 55-61

  Herrmann, K L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RUBELLA VACCINE;

CONGENITAL RUBELLA SYNDROME; FETUS; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION CONTROL; INFECTION RATE; PREGNANCY; REVIEW; RUBELLA; RUBELLA VIRUS; SIDE EFFECT; UNITED STATES; VACCINATION;

DISEASE OUTBREAKS; FEMALE; HUMAN; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RUBELLA; RUBELLA SYNDROME, CONGENITAL; RUBELLA VACCINE; UNITED STATES;

EID: 0025866648     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268800048676     Document Type: Article

References (17)

1. National Communicable Disease Center. Rubella Surveillance Report No. 1. Atlanta, GA: Centers for Disease Control. June 1969.
2. CDC. Rubella and congenital rubella syndrome – United States, 1985–1988. MMWR 1989; 38: 173–178.
3. CDC. Increase in rubella and congenital rubella syndrome – United States, 1988–1990. MMWR 1991; 40: 93–99.
4. Report of the Committee on Infectious Diseases.16th. Evanston.IL:American Academy of Pediatrics,1970.
5. ACIP. Prelicensing statement on rubella virus vaccine. MMWR 1969; 18: 124–125.
6. Orenstein WA, Bart KJ, Hinman AR,, et al The opportunity and obligation to eliminate rubella from the United States. JAMA 1984; 215: 1988–1994.
7. Balfour HH Jr, Groth KE, Edelman CK., et al Rubella viremia and antibody responses after rubella vaccination an reimmunization. Lancet 1981; 1: 1078–1080
8. O'shea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis 1983; 148: 639–647.
9. Greaves WL, Orenstein WA, Hinman AR., et al Clinical efficacy of rubella vaccine. Pediatr Infect Dis 1983; 2: 284–286.
10. Baba K, Yabuuchi H, Okuni H,, et al Rubella epidemic in an institution: protective value of live rubella vaccine and serological behavior of vaccinated, revaccinated, and naturally immune groups. Biken J 1978; 21: 25–31.
11. CDC. Rubella prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990; 39 (no. RR-15): 5–6.
12. Preblud SR. Some issues relating to rubella vaccine. JAMA 1985; 254: 253–256
13. Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA 27/3 rubella virus vaccine. A comparison with strains presently licensed in the U.S. JAMA 1973; 225: 585–590
14. Schaffner W, Fleet WF, Kilroy AW,, et al Polyneuropathy following rubella immunization: a follow-up and review of the problem. Am J Dis Child 1974; 127: 684–688.
15. Tingle AJ, Yang T, Allen M., et al Prospective immunological assessment of arthritis induced by rubella vaccine. Infect Immun 1983; 40: 22–28.
16. Tingle AJ, Allen M, Petty RE. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunization. Ann Rheum Dis 1986; 45: 110–114
17. NCHS. National Health Interview Survey [machine-readable public-use data tape]. Hyattsville, MD: US Department of Health and Human Services, Public Health Service, CDC. 1987.